Eton Pharmaceuticals, Inc.

NasdaqGM ETON

Eton Pharmaceuticals, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2024: USD -5.48 M

Eton Pharmaceuticals, Inc. Net Income is USD -5.48 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -376.82% change year over year. Net income is the total profit earned by a company after deducting all expenses, including taxes and non-controlling interest.
  • Eton Pharmaceuticals, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 1.98 M, a 121.32% change year over year.
  • Eton Pharmaceuticals, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -9.29 M, a 13.05% change year over year.
  • Eton Pharmaceuticals, Inc. Net Income for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -10.68 M.
Key data
Date Net Income EPS (Diluted) Shares (Diluted, Weighted) Net Income Margin
Market news
Loading...
SV Wall Street
NasdaqGM: ETON

Eton Pharmaceuticals, Inc.

CEO Mr. Sean E. Brynjelsen
IPO Date Nov. 13, 2018
Location United States
Headquarters 21925 West Field Parkway
Employees 30
Sector Healthcare
Industries
Description

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Similar companies

BDTX

Black Diamond Therapeutics, Inc.

USD 2.45

-6.49%

NVCT

Nuvectis Pharma, Inc.

USD 6.80

0.59%

CELC

Celcuity Inc.

USD 12.70

6.28%

ALEC

Alector, Inc.

USD 1.64

-1.21%

NUVB

Nuvation Bio Inc.

USD 2.27

-1.73%

ELDN

Eledon Pharmaceuticals, Inc.

USD 4.46

-1.33%

ABOS

Acumen Pharmaceuticals, Inc.

USD 1.50

0.00%

TARS

Tarsus Pharmaceuticals, Inc.

USD 54.14

0.71%

GOSS

Gossamer Bio, Inc.

NA

NA

ELVN

Enliven Therapeutics, Inc.

USD 21.90

0.18%

TVTX

Travere Therapeutics, Inc.

USD 20.22

-1.17%

ALDX

Aldeyra Therapeutics, Inc.

USD 5.17

-1.34%

REPL

Replimune Group, Inc.

USD 13.71

-1.93%

INBX

Inhibrx Biosciences, Inc.

USD 12.72

-6.33%

StockViz Staff

February 5, 2025

Any question? Send us an email